GeoVax Labs, Inc. Earnings Recaps
Q3 2025
Nov 15, 2025
GeoVax reports strong advancements in Q3 2025 across its vaccine portfolio, notably with promising regulatory guidance for its GEO-MVA vaccine, positioning the company for expedited market entry.
Key takeaways
- GEO-MVA vaccine candidate receives expedited development path from EMA, allowing direct progression to Phase III trials.
- Initiated clinical batch preparation for GEO-MVA, with vaccine availability expected early next year for evaluation and potential stockpile needs.
- Continued progress and recognition of GEO-CM04S1 as a vital solution for immunocompromised populations, supported by recent clinical presentations enhancing collaboration opportunities.
- Ongoing discussions with government and international health organizations highlight the strategic importance of U.S.-based vaccine supply chains.